MAPT and neuroblastoma: Dasatinib (18), a drug that targets the SRC family tyrosine kinases YES1 and FYN, has been shown to significantly reduce tau phosphorylation in a neuroblastoma cell line overexpressing the mutant tau protein (Table 1).